Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 New anticoagulant strategies. Current status and future potential.

× No keyword cloud information.

35 in total

1. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin.

Authors: J M Maraganore; P Bourdon; J Jablonski; K L Ramachandran; J W Fenton
Journal: Biochemistry Date: 1990-07-31 Impact factor: 3.162

2. Domains specifying thrombin-receptor interaction.

Authors: T K Vu; V I Wheaton; D T Hung; I Charo; S R Coughlin
Journal: Nature Date: 1991-10-17 Impact factor: 49.962

3. Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris.

Authors: H K Gold; L W Gimple; T Yasuda; R C Leinbach; W Werner; R Holt; R Jordan; H Berger; D Collen; B S Coller
Journal: J Clin Invest Date: 1990-08 Impact factor: 14.808

4. Intravenous and endobronchial administration of G4120, a cyclic Arg-Gly-Asp-containing platelet GPIIb/IIIa receptor-blocking pentapeptide, enhances and sustains coronary arterial thrombolysis with rt-PA in a canine preparation.

Authors: T Yasuda; H K Gold; C Kohmura; L Guerrero; H Yaoita; J T Fallon; S Bunting; D Collen
Journal: Arterioscler Thromb Date: 1993-05

5. Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects.

Authors: R M Lidón; P Théroux; M Juneau; B Adelman; J Maraganore
Journal: Circulation Date: 1993-10 Impact factor: 29.690

6. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.

Authors: P J Hogg; C M Jackson
Journal: Proc Natl Acad Sci U S A Date: 1989-05 Impact factor: 11.205

7. The effect of thrombin inhibitors on tissue plasminogen activator induced thrombolysis in a rat model.

Authors: P Klement; A Borm; J Hirsh; J Maraganore; G Wilson; J Weitz
Journal: Thromb Haemost Date: 1992-07-06 Impact factor: 5.249

8. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.

Authors:
Journal: N Engl J Med Date: 1994-04-07 Impact factor: 91.245

9. Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial.

Authors: E J Topol; V Fuster; R A Harrington; R M Califf; N S Kleiman; D J Kereiakes; M Cohen; A Chapekis; H K Gold; M A Tannenbaum
Journal: Circulation Date: 1994-04 Impact factor: 29.690

10. The structure of a complex of recombinant hirudin and human alpha-thrombin.

Authors: T J Rydel; K G Ravichandran; A Tulinsky; W Bode; R Huber; C Roitsch; J W Fenton
Journal: Science Date: 1990-07-20 Impact factor: 47.728

4 in total

Review 1. Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.

Authors: R Davis; D Faulds
Journal: Drugs Aging Date: 1997-04 Impact factor: 3.923

Review 2. [Therapy of acute coronary syndrome. Aspirin, heparin, low-molecular-weight heparin, hirudin and GP-IIb/IIIa blockers].

Authors: A Gaede; W Terres
Journal: Herz Date: 1999-08 Impact factor: 1.443

3. Antithrombotic effects of BCH 2763, a new direct thrombin inhibitor, in a canine model of venous thrombosis.

Authors: T B McClanahan; D P Ignasiak; P Juneau; C Finkle; P D Winocour; K P Gallagher
Journal: J Thromb Thrombolysis Date: 1999-06 Impact factor: 2.300

4. Effects of Intravenous Enoxaparin and Intravenous Inogatran in an Electrolytic Injury Model of Venous Thrombosis in the Dog.

Authors:
Journal: J Thromb Thrombolysis Date: 1998-11 Impact factor: 2.300

4 in total